Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in...
Abstract Tyrosine kinase inhibitors (TKIs) have transformed the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), yet acquired resistance remains a major clinical limitation. Resistance is increasingly understood as an evolving state shaped not only by tumor-cell genomic alterations but...
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the outcome of...
Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with...
Abstract High-dose EGFR-TKIs have been used as an exploratory therapeutic strategy to overcome the limitations of the standard-dose regimen in the treatment of EGFR-mutant NSCLC, particularly in patients with CNS metastases. Available clinical evidence suggests that high-dose TKIs confer certain...
The quinoline scaffold is widely exploited in the design of new anticancer candidates. As a continuation of our previous work in the search for promising anticancer candidates, we designed novel quinoline-based compounds linked to a range of heterocyclic rings by...
The study described treatment patterns in the private and public setting for patients with NSCLC in Mexico; patients were grouped depending on their ALK and EGFR status. Previous and current treatmen 1 Introduction Lung cancer is the leading cause of...
HERON-Lung01: Ruzaltatug Rezetecan Reduces Progression Risk in EGFR-Mutated NSCLC Following EGFR-TKI Therapy A phase III trial published in The Lancet has demonstrated that the HER3-directed antibody-drug conjugate (ADC) ruzaltatug rezetecan significantly improves progression-free survival compared with platinum-based chemotherapy in patients...
Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC In the phase III PANKU-Lung01 trial, the bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival compared with platinum-based chemotherapy in patients with EGFR-mutated advanced nonsquamous non–small cell lung cancer...
REZILIENT3: First-Line Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC A phase 3 trial of an exon 20-specific oral inhibitor combined with chemotherapy reports improved progression-free survival and response, alongside cytopenias concentrated in the induction phase. In "REZILIENT3: First-Line Zipalertinib...
